ФАРМАЦЕВТИЧЕСКАЯ КОМБИНАЦИЯ ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ИНДУЦИРОВАНИЯ ПОТЕРИ МАССЫ ТЕЛА У СУБЪЕКТОВ С ДИАБЕТОМ 2 ТИПА ИЛИ/И ДЛЯ ПРЕДОТВРАЩЕНИЯ НАБОРА МАССЫ ТЕЛА У СУБЪЕКТОВ С ДИАБЕТОМ 2 ТИПА
1. A pharmaceutical combination for use to improve glucose tolerance in subjects with type 2 diabetes, comprising: (a) desProEksendin-4 (1-39) -Lys-NHili / and a pharmaceutically acceptable salt thereof, and (b) metformin or / and pharmaceutically acceptable salt thereof, wherein the subject to be treated, age 50 years and has the concentration of glucose in plasma after 2 hours after ingestion, of at least 14 mmol / L.2. Pharmaceutical combination according to claim 1, wherein the subject to be treated, a glucose oscillation of at least 2 mmol / l, at least 3 mmol / l, at least 4 mmol / l or at least 5 mmol / l while glucose fluctuation is a difference in the plasma glucose concentration over 2 hours after a meal and glucose concentration in plasma in 30 minutes before the test pischi.3 reception. Pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is suffering ozhireniem.4. Pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated, has a BMI of at least 30 kg / M.5. Pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is adult chelovek.6. Pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is not receiving antidiabetic lechenie.7. Pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated, type 2 diabetes mellitus was diagnosed at least 1 year, or for at least 2 years before terapii.8. Pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has a HbA1c value of about 7 to about 10% .9. Pharmaceutical comb1. Фармацевтическая комбинация для применения для улучшения переносимости глюкозы у субъектов с диабетом 2 типа, содержащая:(а) desPro36Эксендин-4(1-39)-Lys6-NH2 или/и его фармацевтически приемлемую соль, и(b) метформин или/и его фармацевтически приемлемую соль,при этом субъект, подлежащий лечению, моложе 50 лет и имеет концентрацию глюкозы в плазме через 2 часа после п
